Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

3) $(54,529) $(22,170) $(114,729)

Basic and

diluted net

loss per

share $(0.68) $(0.34) $(1.86) $(0.80)

Weighted

average

common

shares

used

in the

calculation

of basic

and

diluted

net loss

per share 30,022 27,797 29,273 27,776

MEDIVATION, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

(unaudited)

September 30, December 31,

2008 2007

ASSETS

Current assets:

Cash and cash equivalents $20,374 $43,258

Prepaid expenses and other current assets 1,683 991

Total current assets 22,057 44,249

Property and equipment, net 728 689

Intellectual property, net 55 58

Other non-current assets 1,195 600

Total assets $24,035 $45,596

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $6,203 $1,747

Accrued expenses 8,793 2,218

Other current liabilities 87 70

Total current liabilities 15,083 4,035

Other non-current liabilities 426 492

Series A redeemable preferred stock 11 11

Total liabilities 15,52
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... , , Catalog Number, Pack ... 100 g, , , , , , ... German , version - 42 K , ... Material Safety , Data Sheets, , MSDS , ...
... , , , , , , , ... , 1691104, Set, ... Package , Inserts/Product Instructions , , English , ... - 24 K , , US Material Safety , Data Sheets , ...
... , Here are some troubleshooting hints that we have gathered , regarding misincorporation or low fidelity of PCR ... , , , , ... , , <a , ... , , , ...
Cached Biology Technology:Trouble-shooting: Misincorporation or low fidelity 2Trouble-shooting: Misincorporation or low fidelity 3
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... 17, 2014The development of stem cell therapies to cure ... characterize stem cell populations based on cell surface markers. ... new marker that is highly expressed in a type ... which they describe in an article in BioResearch ... Liebert, Inc., publishers. The article is available free on ...
(Date:4/17/2014)... Marc Andr Gauthier and Professor Luca Razzari of ... been awarded large grants from the John R. ... Innovation (CFI) for the acquisition of state-of-the-art biotech ... added matching grants from the Ministre de l,Enseignement ... de la Technologie (MESRST). These new laboratories will ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2New state-of-the-art biotech and nanotech equipment for INRS 2
... the body, a virus such as HIV invades body cells ... Once inside the cell, the invading microbe's genetic material takes ... more copies of the virus, which then spill out to ... that once a virus begins fusing with a cell's membrane, ...
... in prospect with a clinical drug trial to begin in ... would open the way to relief in the 10% of ... over 500,000,000 people. , The Walter and Eliza Hall ... Guinea Institute of Medical Research (PNGIMR) and the University of ...
... Medical Center (SFVAMC) and the University of California, San ... bronchitis, which is thought to lead to obliterative bronchitis ... transplanted lungs. , The researchers hope their results will ... standard test for chronic lung rejection, as well as ...
Cached Biology News:Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3Old drug, new tricks: Prospects for slashing the impact of malaria 2Researchers identify genes associated with lung transplant rejection 2
... Labsystems Nepheloskan Ascent is the ... measurement in microplates. Nepheloskan measures ... ultra-sensitive technique for particle quantification. ... solubility testing in drug discovery, ...
... Crotalus adamanteus venom Description: Phosphodiesterase ... used in studying nucleic acid ... It hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ... Phosphodiesterase I cleaves ADP-ribosylated proteins ...
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... Useful for the determination of digitonin and digoxin. ... EDTA Na 4 and 0.06% NaCl Preparation ... al., Biochem. Biophys. Res. Commun., 19, 755 ... mole of inorganic phosphorus from ATP per min ...
Biology Products: